~~<i id='D9DD41DC93'><strike id='D9DD41DC93'><tt id='D9DD41DC93'><pre id='D9DD41DC93'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：focus 2025-09-06 04:38:23 - browse：7

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Google and Epic fight stronger regulation of AI in health care

hotspot

focus

hotspot

focus

hotspot

knowledge

AdobeMosteverythingislookingupforOrexo,thecompanyreportedonitssecondquarterearningscallonTuesday.Tha

WSS

Medicare to cover more brain scans for Alzheimer’s patients

Report cites 'urgent' need to recruit more diverse clinical trial participants

As digital health tech proliferates, a new institute aims to cut through hype

Doctors find melanoma drugs effective against rare brain cancer

Sanofi seeks simpler, safer CRISPR sickle cell cure

Doctors find melanoma drugs effective against rare brain cancer

focus

hotspot

hotspot

How one medical school became remarkably diverse

Custom gene therapy hints at new path for rare disease treatments

The high cost of giving birth even with insurance

Tome Biosciences co

Hollywood unions extend contract negotiations for actors

Why hospitals are withdrawing from US News rankings

Walensky prepares to leave CDC — and Congress — behind

Resistance to opioid

After affirmative action ruling, medical educators look to 'holistic review'

Listen: Wegovy in the brain & pivotal Alzheimer's data

focus

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Custom gene therapy hints at new path for rare disease treatments

Study gives hint on South Asians’ higher risk of cardiovascular disease

Ebola vaccine can save some who are already sick, per new study

STAT Boddities: What happens to the brain when we get scared?

How Medicaid coverage policies for immigrants impact new moms

hotspot

focus

hotspot

knowledge